Lapaʻau ʻana i ka maʻi maʻi ʻāʻī ma ka pae 2026: alakaʻi a me ke kumukūʻai Kina - nā halemai kokoke iaʻu 

ʻO ka mālama ʻana i ka maʻi kanesa ma ka pae ma 2026 e pili ana i nā protocol i hoʻopaʻa ʻia, i hoʻohana ʻia ma Kina e mālama i ka maʻi maʻi maʻi maʻi mua ma muli o ka nui o ka laha. ʻO ka mea hou loa 2026 Nā Kūlana Lapaʻau Pākē Hoʻoikaika i ka neʻe ʻana i ka lāʻau lapaʻau pololei, ka hoʻohui ʻana i nā lāʻau lapaʻau molecular targeted a me immunotherapy me ka chemotherapy a me ka radiation kuʻuna. No ka maʻi maʻi mua, hoʻomau ka hoʻomaʻamaʻa ʻana, ʻoiai ʻo ka hoʻokele Stage IV ke hoʻonohonoho mua nei i ka genetic profiling e koho i nā mālama ʻōnaehana maikaʻi loa, e hoʻonui nui i ke ola a hoʻomaikaʻi i ka maikaʻi o ke ola no nā miliona o nā maʻi.

Ka hoʻomaopopo ʻana i ka maʻi maʻi maʻi maʻi i ka makahiki 2026

ʻO ka hoʻonohonoho pololei ka pōhaku kihi o ka hopena lapaʻau ʻana i ka maʻi ʻaʻai māmā ma ke kahua. Ma 2026, pili paʻa nā poʻe oncologists Kina i ka 9th Edition o ka TNM staging system i hoʻokumu ʻia e ka International Association for the Study of Lung Cancer (IASLC). Hoʻokaʻawale kēia ʻōnaehana i nā ʻōpū ma muli o ka nui (T), ke komo ʻana o ka lymph node (N), a me ka metastasis mamao (M). He mea koʻikoʻi ka hoʻomaopopo ʻana i kēia mau pae no ka mea ʻokoʻa loa nā hoʻolālā therapeutic ma waena o nā ulu kūloko a me nā maʻi ākea.

Paʻakikī ka ʻāina o ka maʻi kanesa ma Kina. Hōʻike ka ʻikepili mai ka National Cancer Center ʻo ka maʻi kanesa ka maʻi maʻi maʻi nui loa, me kahi o 1.06 miliona mau hihia hou a me 733,300 mau make i hoʻopaʻa ʻia i ka makahiki 2022. ʻOiai ka nui o ka ʻike lehulehu e pili ana i ka nānā ʻana, ua ʻike ʻia kahi hapa nui o nā mea maʻi ma Stage IV. No laila, ʻo ka 2026 alakaʻi e kau i ka manaʻo nui i ka hoʻonui ʻana i nā hopena no ka maʻi holomua ʻoiai e hoʻoikaika ana i nā protocol ʻike mua.

ʻO ka hoʻololi ʻana i ka lāʻau lapaʻau pololei

Ua ulu ka wehewehe o ka mālama maʻamau. ʻOiai ʻo ka chemotherapy wale nō ka iwi kuamoʻo o ka lāʻau lapaʻau, ʻike ka 2026 update i kēlā molecular targeted therapy a immunotherapy he mau kia waena. ʻAʻole hoʻokumu wale ʻia nā hoʻoholo lapaʻau ma ka mōʻaukala (e like me ka adenocarcinoma vs. squamous cell carcinoma) akā ua alakaʻi ʻia e nā hoʻololi genetic kikoʻī. ʻO kēia hoʻololi paradigm e hōʻoia i ka loaʻa ʻana o nā maʻi i nā lāʻau lapaʻau maikaʻi loa no kā lākou biology tumor kikoʻī.

Nā Kūkākūkā Lapaʻau ʻana i ka maʻi maʻi maʻi maʻi mua

No nā poʻe maʻi i loaʻa i ka Stage I a me ka Stage II non-small cell lung cancer (NSCLC), ʻo ka pahuhopu mua ka hoʻōla. Ua hōʻoia hou nā alakaʻi Kina i ka makahiki 2026, ʻo ka ʻoki ʻoki ʻana ke kumu gula no nā moho hoʻohana. Eia naʻe, ua lilo ka hoʻokokoke ʻana i ka ʻoki a me ka adjuvant therapy e hoʻonui i ke ola lōʻihi.

Nā Hana ʻokiʻoki a me nā ʻenehana hōʻemi liʻiliʻi

ʻO ka ʻoki ʻana ke ʻano hana maikaʻi loa no ka wehe ʻana i nā maʻi maʻi mua. I loko o nā keʻena lapaʻau nui Kina, ua lilo ʻo Video-Assisted Thoracoscopic Surgery (VATS) a me Robot-Assisted Thoracic Surgery. ʻO kēia mau ʻano hana invasive liʻiliʻi e hōʻemi i ka manawa hoʻihoʻi a me nā pilikia e hoʻohālikelike ʻia me ka thoracotomy wehe kuʻuna.

• Lobectomy: ʻO ka wehe ʻana i kahi lobe holoʻokoʻa o ka māmā ke kaʻina hana maʻamau no ka hapa nui o nā hihia Stage I a me II.
• Hoʻokaʻawale ʻia: No nā maʻi maʻi liʻiliʻi a i ʻole nā ​​maʻi me ka hana o ka māmā liʻiliʻi, ʻae ʻia ka wehe ʻana i kahi ʻāpana o ka lobe.
• ʻO ka wehe ʻana i ka ʻōpū o ka Lymph: Pono ka hoʻoheheʻe ʻana a i ʻole ka wehe ʻana o nā ʻōpū lymph mediastinal no ka hoʻonohonoho pono ʻana a me ka hoʻomalu kūloko.

Hoʻolālā Adjuvant Therapy

ʻO ka mālama ʻana ma hope o ka ʻoki ʻana, i kapa ʻia ʻo adjuvant therapy, he mea koʻikoʻi no ka hoʻopau ʻana i ka maʻi microscopic a pale i ka hoʻi hou ʻana. Hāʻawi nā alakaʻi 2026 i nā manaʻo hou e pili ana i nā hoʻokolohua lapaʻau hou.

No nā maʻi o Stage IB a i IIIA me nā hoʻololi genetic kikoʻī, e like me ka EGFR positivity, adjuvant targeted therapy ua paipai ikaika ʻia i kēia manawa. Hōʻike kēia i kahi holomua nui ma mua o nā makahiki i hala kahi o ka chemotherapy wale nō ke koho. Pēlā nō, no nā poʻe maʻi me ka ʻole o ka hoʻololi ʻana i ke kaʻa akā me ka ʻōlelo PD-L1 kiʻekiʻe, immunotherapy kōkua Hiki ke hoʻohana ʻia ma hope o ka chemotherapy e pili ana i ka platinum.

Hoʻoponopono i ka maʻi maʻi maʻi ʻāʻī kūloko

Hōʻike ʻia ka maʻi maʻi maʻi maʻi maʻi maʻi III i kahi hiʻohiʻona paʻakikī kahi i laha ai ka maʻi i nā ʻōpū lymph kokoke akā ʻaʻole i nā kino mamao. Ua kapa pinepine ʻia kēia ʻano "locally advanced." Pono ke ala lapaʻau i kahi hui multidisciplinary e pili ana i nā kauka lapaʻau, nā kauka oncologists, a me nā oncologists radiation.

Ka Hana o ka Multimodal Therapy

ʻO ka pōhaku kihi o ka Stage III lapaʻau lapaʻau multimodal, e hoʻohui i nā ʻano hana lapaʻau like ʻole. ʻO ke kaʻina kikoʻī e pili ana i ka manaʻo ʻia o ka maʻi maʻi e hiki ke wehe ʻia.

• Hiki ke wehe hou ʻia ka pae III: Hiki i nā poʻe maʻi ke hana i ka lāʻau neoadjuvant (chemotherapy a i ʻole chemo-immunotherapy) e hōʻemi i ke koko ma mua o ke kaʻe ʻana. Ma hope o ka wehe ʻana, hāʻawi ʻia ka lāʻau adjuvant hou.
• Māhele III hiki ʻole ke wehe ʻia: No nā poʻe maʻi ʻaʻole hiki ke hoʻopaʻa ʻia ma muli o ka wahi tumo a i ʻole ke kūlana olakino, concurrent chemoradiotherapy (cCRT) ka maʻamau o ka mālama.

Hoʻohui Immunotherapy

ʻO kahi holomua i ka mālama ʻana i ka maʻi Stage III hiki ʻole ke hoʻohana ʻia ka hoʻohana ʻana i ka immunotherapy consolidation. Ma hope o ka hoʻopau ʻana i ka chemoradiotherapy concurrent, mālama ʻia nā mea maʻi i holomua ʻole me nā mea hoʻopaʻapaʻa pale pale. Hōʻike nā alakaʻi o 2026 i kēia hoʻolālā ma ke ʻano he hana koʻikoʻi i hoʻomaikaʻi nui i ke ola holomua ʻole a me nā helu ola holoʻokoʻa i ka heluna kanaka Kina.

ʻO ka maʻi maʻi maʻi maʻi maʻi IV: Systemic Treatment Revolution

ʻO ka pae IV, a i ʻole ka maʻi maʻi maʻi maʻi metastatic, hiki i ka wā e laha ai ka maʻi i nā ʻano mamao e like me ka lolo, iwi, ate, a i ʻole ka māmā ʻē aʻe. Ma ka mōʻaukala, ʻaʻole maikaʻi ka wānana no ka Stage IV, me nā manawa ola kūlohelohe mai ka 1 a 3 mau mahina wale nō. Eia naʻe, ʻo ka 2026 Nā Kūlana Lapaʻau Pākē e noʻonoʻo i kahi hoʻololi nui i nā hopena ma muli o ka holomua o nā ʻōnaehana systemic.

ʻO ka hoʻāʻo ʻana i ka Molecular ma ke ʻano he koi

Ma mua o ka hoʻomaka ʻana i kekahi lāʻau lapaʻau no Stage IV NSCLC, pono ka hoʻāʻo ʻana i ka molecular piha. Manaʻo nā alakaʻi i ka biopsy kiko a i ʻole ka biopsy wai (hoʻāʻo koko) pono e ʻike i ka hoʻololi ʻana o ka mea hoʻokele. ʻO nā pahu hopu maʻamau ka EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, a me NTRK.

No ke aha he mea nui ka hoʻāʻo ʻana: ʻO ka ʻike ʻana i kahi hoʻololi kikoʻī e hiki ai i nā kauka ke kuhikuhi i nā lāʻau lapaʻau i manaʻo ʻia i ʻoi aku ka maikaʻi a ʻoi aku ka ʻona ma mua o ka chemotherapy maʻamau. No nā poʻe maʻi me ka ʻole o ka hoʻololi ʻana, alakaʻi ka hoʻāʻo PD-L1 i ka hoʻohana ʻana i ka immunotherapy.

Nā Koho Lapaʻau Kūlohelohe

Hoʻokomo ka 2026 update i nā lāʻau lapaʻau hou a pau i ʻae ʻia e ka National Medical Products Administration (NMPA) o Kina a hiki i ka hopena o 2025. ʻO kēia mau mea e pili ana i nā mea hoʻopaneʻe EGFR o nā hanauna ʻekolu a me nā mea hoʻopaneʻe ALK e hiki mai ana i loaʻa ka mana kiʻekiʻe e komo i ka pale koko-lolo.

• Nā hoʻololi EGFR: ʻO ka lāʻau lapaʻau mua e pili ana i nā mea hoʻopaneʻe tyrosine kinase (TKIs). Ua hōʻike kēia mau lāʻau lapaʻau i ka maikaʻi o ka mālama ʻana i nā maʻi intrathoracic a me nā metastases lolo.
• ALK hoʻonohonoho hou: ʻO nā mea hoʻopaneʻe ALK ikaika i kēia manawa ka maʻamau, e hāʻawi ana i ka mālama maʻi lōʻihi a me nā helu pane kiʻekiʻe.
• Nā pahuhopu ʻē aʻe: Loaʻa nā mea hoʻopaneʻe kikoʻī no ROS1, BRAF V600E, MET exon 14 skipping, a me RET fusion positives.

Nā Hui Immunotherapy

No nā poʻe maʻi i nele i ka hoʻololi ʻana o ka mea hoʻokele, ua lilo ka immunotherapy i hui pū ʻia me ka chemotherapy i ka maʻamau hou. Manaʻo nā alakaʻi i nā regimens like ʻole e pili ana i ka subtype histological (squamous vs. non-squamous) a me nā pae hōʻike PD-L1. I nā hihia o ka hōʻike PD-L1 kiʻekiʻe, hiki ke noʻonoʻo ʻia ka monotherapy immunotherapy e hoʻopakele i nā maʻi mai ka lāʻau make chemotherapy.

Ka Manaʻo Kūikawā: Lung Cancer Brain Metastases

ʻO nā metastases lolo he mea maʻamau a paʻakikī hoʻi o ka maʻi maʻi ʻāʻī, e pili ana i ka hapa nui o nā mea maʻi Stage IV. I Ianuali 2026, ua hoʻokuʻu ʻo Kina i ka hoʻolaʻa "Nā Kūlana Lapaʻau Kina no nā Metastases Brain Cancer Lung (2026 Edition)". Hoʻopuka kēia palapala i nā pilikia kūikawā o ka mālama ʻana i ka maʻi kanesa i laha i ka lolo.

Nā Kūlana diagnostics

Hōʻike maopopo nā alakaʻi i kēlā ʻO ke kiʻi ʻana i ka manaʻo hoʻopaneʻe mākēneki (MRI) ʻO ke poʻo ke ʻano kiʻi kiʻi i makemake ʻia no ka ʻike ʻana a me ka nānā ʻana i nā metastases o ka lolo. ʻAʻole lawa nā CT scans no ka ʻike ʻana i nā liʻi liʻiliʻi. Manaʻo ʻia ka nānā ʻana i ka MRI maʻamau no nā poʻe maʻi kiʻekiʻe me ka ʻole o nā hōʻailona neurological.

Lapaʻau Hierarchy

Pono ka mālama ʻana i nā metastases lolo i kahi ala kūpono e hui pū ai i nā lāʻau lapaʻau kūloko a me ka ʻōnaehana:

• ʻO ka lāʻau lapaʻau: ʻO nā lāʻau lapaʻau i manaʻo ʻia e nā hanauna hou me ke komo ʻana o ke koko-lolo kiʻekiʻe ka lālani mua o ka pale ʻana no nā poʻe maʻi me nā hoʻololi hoʻokele. Hiki iā lākou ke hōʻemi pono i nā ʻeha o ka lolo me ka ʻole e pono koke i ka radiation.
• ʻO ka radiosurgery: ʻO ka Steeotactic Radiosurgery (SRS) ka mea i makemake ʻia no nā helu liʻiliʻi o nā metastases. Hāʻawi ʻo ia i ka radiation kiʻekiʻe i ka maʻi maʻi ʻoiai e mālama ana i ka ʻiʻo lolo olakino.
• ʻO ka lāʻau lapaʻau lolo holoʻokoʻa (WBRT): Mālama ʻia no nā poʻe maʻi me ka nui o nā metastases a i ʻole ka maʻi leptomeningeal, ʻoiai ke hoʻoikaika ʻia nei e hōʻemi i nā hopena ʻaoʻao cognitive.
• Ka lāʻau neʻe: Noʻonoʻo ʻia ka ʻoki ʻoki ʻana no nā ʻeha nui a me nā hōʻailona e hoʻoulu ai i ka hopena nui a i ʻole no nā kumu diagnostic ke ʻike ʻole ʻia ka maʻi maʻi mua.

Nā Kānāwai Liʻiliʻi Pūnaehana Lung Cancer (SCLC).

ʻOiai ʻo ka Non-Small Cell Lung Cancer (NSCLC) e pili ana i ka 85% o nā hihia, Small Cell Lung Cancer (SCLC) he ʻano subtype ʻokoʻa a koʻikoʻi. Mālama nā alakaʻi 2026 i kahi ala ʻokoʻa no SCLC ma muli o kona ulu wikiwiki a me ka metastasis mua.

Ka Papa Palekana vs

Hoʻokaʻawale ʻia ʻo SCLC i loko o ka palena palena (paʻa i hoʻokahi hemithorax) a me ka pae nui (hoʻolaha ʻia ma waho).

• Kau palena ʻole: ʻO ka maʻamau o ka mālama ʻana he chemoradiotherapy concurrent. Hiki ke noʻonoʻo ʻia ka prophylactic cranial irradiation (PCI) no nā mea pane e pale i ka metastases o ka lolo.
• Ka Papa Nui: Hoʻopili ka mālama ʻana i ka chemotherapy systemic i hui pū ʻia me ka immunotherapy. ʻO ka hoʻohui ʻana o nā mea hoʻopaʻapaʻa pale pale i ka platinum-etoposide chemotherapy ua lilo i ka pae honua a me Kina, e hoʻomaikaʻi ana i ke ola holoʻokoʻa.

ʻO ke kumukūʻai o ka mālama ʻana i ka maʻi maʻi maʻi ma Kina

He mea nui ka hoʻomaopopo ʻana i ka ʻaoʻao kālā no nā poʻe maʻi e ʻimi nei lapaʻau ʻana i ka maʻi ʻaʻai māmā ma ke kahua ma Kina. Hoʻololi nui ke kumukūʻai ma muli o ke kahua, ke ʻano o ka mālama ʻana, ka pae o ka haukapila, a me ka uhi ʻinikua. Ua holomua nui ka ʻōnaehana olakino o Kina i ka hōʻemi ʻana i ke kaumaha o ka maʻi ma o ka National Reimbursement Drug List (NRDL).

Hoʻokaʻawale i nā kumukūʻai lapaʻau

ʻOi aku ka haʻahaʻa o nā kumukūʻai ma Kina i hoʻohālikelike ʻia i nā ʻāina Komohana, ʻoi aku hoʻi no nā lāʻau lapaʻau hou i hoʻokomo ʻia i loko o ka papahana ʻinikua aupuni.

• ʻO ka ʻoki ʻana: ʻO ka liʻiliʻi invasive lobectomy maʻamau mai 40,000 a 80,000 RMB ($ 5,500 - $ 11,000 USD), ma muli o ka paʻakikī a me ka pae o ka haukapila. Mālama ka 'inikua i kahi hapa nui.
• Kemoterapi: ʻO nā regimens chemotherapy kuʻuna he mea kūʻai nui loa, e kūʻai pinepine ana i kahi mau tausani RMB i kēlā me kēia pōʻai ma hope o ka uku hou ʻana.
• ʻO ka lāʻau lapaʻau i koho ʻia: Ma mua o ka hoʻokomo ʻana i ka NRDL, ua pāpā ʻia kēia mau lāʻau lapaʻau. I kēia manawa, uhi ʻia nā TKI kī nui, e hōʻemi ana i nā kumukūʻai o waho o ka ʻeke ma waena o 2,000 a me 5,000 RMB ($280 - $700 USD) no nā maʻi he nui.
• Immunotherapy: ʻO nā mea hoʻopaneʻe PD-1 o ka home he kumu kūʻai maikaʻi loa, me kekahi mau pōʻai e kūʻai ana ma lalo o 3,000 RMB ($420 USD) ma hope o ka ʻinikua. ʻOi aku paha ke kiʻekiʻe o nā lāʻau i lawe ʻia mai akā hiki ke loaʻa.
• Lapaʻau Radiation: ʻO nā papa o IMRT a i ʻole SBRT maʻamau mai 20,000 a 50,000 RMB ($2,800 - $7,000 USD).

'Inikua a me ka hiki

ʻO ka ʻōnaehana ʻinikua Lapaʻau kumu ma Kina e uhi i ka nui o nā lāʻau anti-cancer. ʻO nā alakaʻi 2026 e noʻonoʻo pono i ka loaʻa ʻana o ka lāʻau lapaʻau a me ke kūlana uku hou i ka wā e hana ai i nā manaʻo. Paipai ʻia nā poʻe maʻi e kūkākūkā me nā limahana limahana o ka haukapila a i ʻole nā ​​​​mea loea inikua e hoʻonui i kā lākou mau pono. Eia kekahi, ʻo ka ʻinikua hoʻohui pāʻoihana a me nā papahana kōkua manawaleʻa e hōʻemi hou i ka ʻona kālā no nā ʻohana.

Ke ʻimi nei i nā halemai a me nā loea ma kahi kokoke iā ʻoe

He mea nui ka loaʻa ʻana o ka mālama kiʻekiʻe no nā hopena maikaʻi loa. Ua hoʻokiʻekiʻe ʻo Kina i kekahi mau kikowaena maʻi maʻi honua e alakaʻi ana i ka noiʻi a me ka noi ʻana o nā alakaʻi 2026. I ka huli ana nā halemai kokoke iaʻu, Pono nā poʻe maʻi e ʻimi i nā keʻena me nā keʻena oncology thoracic kūikawā.

Nā Kikowaena Oncology Papa Kiʻekiʻe

Ua ʻike ʻia kekahi mau halemai ma Kina no ko lākou ʻike i ka hoʻokele ʻana i ka maʻi kanesa:

• Cancer Hospital, Chinese Academy of Medical Sciences (Beijing): He alakaʻi i ka hoʻokumu ʻana i nā alakaʻi āpau a me ka hoʻokele hihia paʻakikī.
• Ke Kula Nui ʻo Fudan Shanghai Cancer Center: Kaulana ʻia no kona ʻano hoʻohui ʻia a me nā ʻano hana ʻokiʻoki kiʻekiʻe.
• ʻO ka Halemai Kolepa Lapaʻau o Peking Union: Hāʻawi i nā hui multidisciplinary piha me ka neurosurgery no ka metastases lolo.
• Halemai Kina Komohana (Ke Kulanui ʻo Sichuan): ʻO kahi hub nui no ke komohana Kina, e hāʻawi ana i ka radiation ʻokiʻoki a me ka oncology lapaʻau.

Pehea e koho ai i ka pono kūpono

Ke koho ʻana i kahi haukapila, e noʻonoʻo i kēia mau kumu:

• Hui Pūʻulu Nui (MDT): E hōʻoia i ka mālama ʻana o ka haukapila i nā hālāwai MDT maʻamau kahi e hui pū ai nā kauka lapaʻau, oncologists, a me radiologists i kāu hihia.
• Pathology a me Genetics hiki: Pono e loaʻa nā labs holomua no ka hoʻāʻo molekala wikiwiki a pololei.
• Loaʻa i ka hoʻāʻo lāʻau lapaʻau: Hāʻawi pinepine nā halemai kiʻekiʻe i ke komo ʻana i nā hoʻokolohua lapaʻau hou loa no nā maʻi i pau i nā koho maʻamau.
• Nā lawelawe kākoʻo: E ʻimi i nā halemai e hāʻawi ana i ke kākoʻo meaʻai, hoʻokele ʻeha, a me ka ʻōlelo aʻo noʻonoʻo.

Hoʻohālikelike Hoʻohālikelike o nā ʻano Lapaʻau

No ka hoʻomaopopo maikaʻi ʻana i nā koho i loaʻa ma lalo o nā alakaʻi 2026, ua hoʻohālikelike ka papa ma lalo nei i nā ʻano hana lapaʻau mua i hoʻohana ʻia ma Kina i kēia lā.

ʻO ka huakaʻi hele maʻi i ka makahiki 2026

ʻO ka hoʻokele ʻana i ka ʻōnaehana olakino hiki ke paʻakikī. Aia ma lalo kahi ala maʻalahi no ka mea maʻi i manaʻo ʻia he maʻi maʻi maʻi maʻi ma Kina, i kūlike me nā alakaʻi hou loa.

• KaʻAnuʻu 1: Nānā a me ka hōʻoia ʻana: Loaʻa ka poʻe pilikia nui (makahiki 50+, nā mea puhi paka) i ka Low-Dose Spiral CT (LDCT). Inā ʻike ʻia kahi nodule, e hana hou ʻia ke kiʻi a me ka biopsy.
• KaʻAnuʻu 2: Hoʻonohonoho i ka hana: Ke hoʻopaʻa ʻia ka maʻi kanesa, mālama ʻia ka PET-CT, MRI lolo, a me nā iwi scans e hoʻoholo ai i ka pae TNM.
• KaʻAnuʻu 3: Hoʻoponopono Molecular: Hoʻouna ʻia ka ʻili a i ʻole nā laʻana koko no ka hoʻāʻo genetic e ʻike i nā hoʻololi e like me EGFR a i ʻole ALK.
• KaʻAnuʻu 4: Kūkākūkā Multidisciplinary: Hoʻoponopono ka hui MDT i nā ʻikepili a pau e hoʻolālā i kahi hoʻolālā lapaʻau pilikino e pili ana i nā alakaʻi 2026.
• KaʻAnuʻu 5: Hoʻomaka Lapaʻau: Hoʻomaka ka lāʻau lapaʻau (ʻokiʻoki, lāʻau lapaʻau, a i ʻole radiation). Hoʻokō koke ʻia ka nānā ʻana no nā hopena ʻaoʻao.
• KaʻAnuʻu 6: Ka hahai ʻana a me ka nānā ʻana: ʻO ke kiʻi maʻamau a me nā hoʻāʻo koko e nānā i ka pane. Hoʻoponopono ʻia ka lāʻau inā loaʻa ka holomua a kūʻē paha.

Nā Pōmaikaʻi a me nā Paʻakikī o nā Kūlana o kēia manawa

ʻO ka hoʻokō ʻana i nā alakaʻi 2026 e lawe mai i nā pōmaikaʻi koʻikoʻi akā hāʻawi pū kekahi i nā pilikia e pono ai nā mea maʻi a me nā mea hoʻolako.

Ka ikaika o ka 2026 Approach

• Hana pilikino: Hoʻopili ʻia nā lāʻau lapaʻau i ka genetic makeup o kēlā me kēia kanaka, e hoʻonui i ka pono.
• Hoʻomaikaʻi i ke ola: ʻO ka hoʻohui ʻana o nā lāʻau lapaʻau hou i hōʻike ʻia i hoʻonui i ke ola o nā maʻi maʻi Stage IV.
• Ka maikaʻi o ke ola: ʻOi aku ka liʻiliʻi o nā hopena koʻikoʻi ma mua o nā lāʻau lapaʻau i manaʻo ʻia a me nā immunotherapies.
• Hoʻohālikelike: ʻO nā alakaʻi aupuni hui ʻia e hōʻoia i ka loaʻa ʻana o nā maʻi ma nā wahi like ʻole i ka mālama kūlana kiʻekiʻe.

Nā wahi e hoʻomaikaʻi ai

• Ka helu o ka ʻike mua ʻana: ʻOiai nā alakaʻi, nui ka poʻe maʻi i loaʻa i ka maʻi hope loa ma muli o ka haʻahaʻa o ke komo ʻana i ka screening.
• Kūʻē Laʻau: Hoʻokumu ka puʻupuʻu i ke kū'ē i nā lāʻau lapaʻau i hoʻopaʻa ʻia, pono i nā hoʻolālā laina lua paʻakikī.
• Nā ʻokoʻa kūloko: Hiki ke ʻokoʻa ka loaʻa ʻana i ka hoʻāʻo genetic holomua a me nā lāʻau lapaʻau hou ma waena o nā kūlanakauhale kiʻekiʻe a me nā wahi kuaʻāina.
• Hoʻoponopono i nā hopena ʻaoʻao: ʻOiai i hoʻomaikaʻi ʻia, pono nā hanana ʻino e pili ana i ka immune i ka loea hoʻokele kūikawā.

ʻO ke koʻikoʻi o ka nānā mua ʻana

Hoʻoikaika nui nā alakaʻi 2026 i ka pale a me ka ʻike mua. Ua hoʻopuka ka National Health Commission i nā hoʻolālā kikoʻī no ka nānā ʻana i ka maʻi kanesa o ka maʻi maʻi, e ʻimi ana i ka poʻe kiʻekiʻe. ʻO ka ʻike mua ke ala hoʻokahi e hoʻomaikaʻi ai i ka helu ola ola 5 makahiki.

ʻO wai e pono ke kiʻi ʻia?

Manaʻo ʻia ka nānā ʻana no nā poʻe makahiki 50 a hiki i 74 e hālāwai me hoʻokahi o nā pae hoʻohālike:

• ʻO ka moʻolelo puhi paka o ≥20 mau ʻeke-makahiki (me ka poʻe puhi puhi mua i haʻalele ma lalo o 15 makahiki aku nei).
• ʻIke lōʻihi i ka uahi lua (e noho ana a hana pū paha me nā mea puhi paka no ≥20 makahiki).
• Moolelo o ka ma'i ma'i obstructive pulmonary (COPD).
• ʻO ka ʻike ʻana i ka hana i nā carcinogens e like me asbestos, radon, a me nā metala kaumaha.
• ʻO ka moʻolelo ʻohana o ka maʻi kanesa maʻi maʻi ma nā ʻohana mua.

Manaʻo ʻia ke ʻano no ka nānā ʻana

CT Spiral Haʻahaʻa Haʻahaʻa (LDCT) ʻo ia wale nō ke ʻano o ka nānā ʻana. Hoʻopau ʻia nā hihi-X o ka umauma no ka mea e poina ana lākou i nā nodule mua. Hōʻike nā alakaʻi e hana ʻia ka LDCT me ka hoʻohana ʻana i nā scanners me nā lālani ʻike maka he 16 a i ʻole, i unuhi ʻia e nā radiologist ʻike.

Nā kuhikuhi e hiki mai ana a me nā lāʻau lapaʻau e hiki mai ana

Ke holomua nei mākou a hiki i ka makahiki 2026, hoʻomau ka ulu ʻana o ke kahua o ka mālama ʻana i ka maʻi kanesa. Ke nānā nei ka noiʻi i ka lanakila ʻana i ke kūʻē ʻana i ka lāʻau lapaʻau, ka hoʻohui ʻana i nā lāʻau lapaʻau no nā hopena synergistic, a me ka hoʻomohala ʻana i nā lāʻau lapaʻau.

Ke puka mai nei nā hui lāʻau antibody-drug (ADCs) ma ke ʻano he papa lāʻau ikaika hou, e hōʻike ana i ka ʻōlelo hoʻohiki i nā poʻe maʻi i hāʻule i nā lāʻau lapaʻau mua. Eia kekahi, ke hoʻohui ʻia nei ka naʻauao artificial i ka radiology e ʻike i nā nodules ma mua a wānana pololei i nā pane lapaʻau.

ʻO ka hoʻokō ʻana o nā hui lapaʻau Kina e hoʻomaikaʻi mau i nā alakaʻi e hōʻoia i ka pōmaikaʻi o nā poʻe maʻi mai nā hanana ʻepekema hou loa me ka kali ʻole. ʻO ka hui pū ʻana ma waena o nā hui lāʻau lapaʻau kūloko a me nā hui noiʻi honua e wikiwiki nei i ka loaʻa ʻana o nā lāʻau lapaʻau hou i loko o Kina.

Ka hopena

ʻO ka ʻāina o lapaʻau ʻana i ka maʻi ʻaʻai māmā ma ke kahua i 2026 ua wehewehe ʻia e ka pololei, ka pilikino, a me ka manaʻolana. ʻO ka hoʻokuʻu ʻana o ka 2026 Nā Kūlana Lapaʻau Pākē hōʻailona i kahi mea nui, hoʻohui i nā makahiki o ka noiʻi i nā ala lapaʻau hiki ke hana. Mai ka hiki ke ho'ōla i ka ʻoki ʻana i ka wā mua a hiki i ka hiki ke hoʻolōʻihi i ke ola o ka lāʻau lapaʻau i kuhikuhi ʻia a me ka immunotherapy ma Stage IV, ʻoi aku ka nui o nā koho ma mua o nā mea maʻi i kēia lā.

ʻOiai ke hoʻomau nei nā paʻakikī e like me ka nui o ka ʻike mua ʻana a me ke kūʻē ʻana i ka lāʻau, ʻo ke ala i hoʻolālā ʻia e alakaʻi ʻia e ka poʻe oncologists Kina e hāʻawi i kahi ʻano paʻa no ka mālama. Ma ka hoʻohana ʻana i nā diagnostics kiʻekiʻe, e pili ana i nā protocol standardized, a me ka hoʻohana ʻana i ke kākoʻo piha o ka ʻōnaehana mālama olakino, ke hoʻomau nei ka prognosis no nā maʻi maʻi maʻi maʻi maʻi ma Kina. No ka poʻe i loaʻa i kēia maʻi, ʻo ka hoʻomaopopo ʻana i kēia mau pae a me nā lāʻau lapaʻau i loaʻa ka hana mua i ka hoʻokele ʻana i ka huakaʻi me ka hilinaʻi a loaʻa i ka mālama maikaʻi loa.